- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our monthly e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Authors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- David Thomas
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Timothy Coetzee
- Tracy Cooley
Tags
greenhouse gas emissions renewable fuel standard Plant biotechnology One-on-One's global food crisis Climate Change biotechnology agriculture Greenhouse Gas Emission Food and Fuel indirect land use change Biofuel Technology Animal biotechnology BIO Investor Forum Partnering ethanol Food Benefits of biotech crops BIO
Tag Archives: BIO Investor Forum
Opportunity or Apocalypse? Prophecies for 2012
On day two of the BIO Investor Forum in San Francisco, Calif., attendees were eager to participate in the Closing Plenary. Historically, this session draws the biggest crowd of the conference and this year was no exception. Speaking to a packed audience, with standing room only, the panelists engaged in a lively discussion about the state of the industry and what is in the cards for 2012. Both Bryan Roberts, PhD, Partner, Venrock and Matthew Read More >
Beyond the ABCs of ADCs
The recent FDA approval of Seattle Genetics’ antibody, Adcetris, has cast the spotlight on Antibody Drug Conjugates (ADC), leaving experts to contemplate whether this is the peak for ADCs. If history has its say though, the spotlight won’t be flickering anytime soon. Experts in this specialized antibody field discussed the latest developments and lessons of bringing ADCs through the clinic at this week’s 10th Annual BIO Investor Forum. Antibody drug conjugates hold enormous potential for treating Read More >
Resistance is Futile – SuperDrugs for SuperBugs
“MRSA’s kill 100,000 people a year, more than AIDS,” said Mark Leuchetenberger, President and CEO, Rib-X Pharmaceuticals, Inc. With new superbugs on the rise and new superdrugs continuing to decline, the antibacterial drug discovery market is anyone’s for the taking. Attendees of the 10th Annual BIO Investor Forum participating in the Infectious Disease Therapeutic Workshop heard from an engaging panel that seemed to agree the economics of this category are driven by two things: society expects Read More >
Developing Cancer Therapies and Diagnostics: 4 Pieces of Advice
Insights in to the molecular and genetic basis of disease are driving new product and therapeutic opportunities while changing the treatment paradigm for many cancers. The use of companion diagnostics in oncology may play a role in optimizing and expediting the development of targeted therapies for many cancers and other conditions. Focusing on these new markets, a panel of industry executives and investors at the 2011 BIO Investor Forum discussed some of the most compelling Read More >
Multiple Assets Diversify the Deal
With a recent surge in pharma companies collaborating earlier on with small biotech companies, discovery stage partnering deals are becoming increasingly popular. Striking a discovery stage deal can be extremely beneficial for both parties in today’s environment – pharma gets to fill its ever elusive R&D pipeline as patent expirations loom, and the small biotech struggling to raise money to stay alive gets the capital infusion necessary to stay in play. Panelists in the “Broad Read More >
